| abstract |
Provided are therapeutic and pharmaceutical combinations for the treatment of acute leukemia, eg, acute myeloid leukemia, and myelodysplastic syndrome. The therapeutic and pharmaceutical combination employs an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of anthracyclines and pyrimidines or purine nucleoside analogs. A preferred therapy and pharmaceutical combination uses gemtuzumab ozogamicin, daunorubicin and cytarabine. |